

# 6.1.2 Antimicrobial Stewardship

# Antimicrobial Stewardship

Intervention Type	1 <sup>st</sup> Q23	2 <sup>nd</sup> Q23	3 <sup>rd</sup> Q23	4 <sup>th</sup> Q23	12 Month Total
De-escalation	350	359	326	315	1350
Dose adjustment	3,123	2,991	2,975	2,995	12,084
Bug-Drug mismatch	121	135	122	142	520
IV to PO conversion	488	444	410	582	1,924
Therapeutic duplication	138	116	87	100	441
<b>Totals</b>	<b>4,220</b>	<b>4,045</b>	<b>3,920</b>	<b>4,134</b>	<b>16,319</b>

# Antimicrobial Stewardship

## FORMULARY UPDATES

- Systemwide Standardization of Restricted Antimicrobials: BHMC, CSMC, BHN, BHIP standardized restricted antimicrobials across system
- Fidaxomicin restriction criteria (updated)
- Pyrimethamine restriction to ID

## POWERPLANS

- MED CDI (updated)
- EMR Community Acquired Pneumonia (updated)

## QUALITY IMPROVEMENT

- The NHSN Antimicrobial Use (AU) and Antimicrobial Resistance (AR) (AUR) Module reporting to CMS. Interoperability reporting required by 2024
- Ongoing evaluation of ASP Joint Commission requirements and standards
- Ongoing: COVID-19 Treatment Consent Education
- Truvada and Descovy billing based on indication (PrEP vs. Treatment)